NEW YORK (GenomeWeb News) — Inverness Medical Innovations today said that the required waiting period has expired on its proposed offer to buy Biosite without the need for additional information.
 
The company said on May 18 it would acquire Biosite for $92.50 share after a protracted bidding war with Beckman Coulter ended in its favor.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.